South Plainfield, NJ -- February 18, 2013 -- GENEWIZ, Inc., leading global genomic service provider, announced today expansion of their Next Generation Sequencing service portfolio to include exome sequencing. An ideal tool for researchers who require comprehensive information about genomic variations, exome sequencing is an efficient and effective alternative to sequencing the entire genome.
Enabling researchers to target coding regions of the genome, as well as flanking untranslated regions (UTRs), exome sequencing is a powerful method to explore genetic mutations and variants, such as SNPs and Indels, which are present in many complex human diseases. The exome comprises only 2% of the human genome, yet houses as many as 85% of disease-related traits, thus providing a thorough picture of genome-wide variations with significantly less data output and for a lower cost than whole genome sequencing.
"Exome sequencing informs researchers of primarily dominant genetic variations in human diseases that were previously undiscovered," stated Dr. Yankai Jia, Director of GENEWIZ Next Generation Sequencing. "With customizable service offerings, comprehensive data analysis options, and consistent communication with our specialized experts, clients can feel confident entrusting their exome sequencing projects to GENEWIZ."
Accepting a wide variety of sample types, including highly degraded FFPE DNA, GENEWIZ provides "one-stop" exome sequencing services from DNA extraction through custom data analysis. GENEWIZ leads the market for project turnaround time, and even offers express turnaround for select projects.
For more information about GENEWIZ exome sequencing services and offers, please click here.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.